Impact of baseline plasma HIV-1 RNA and time to virological suppression on virological rebound according to first-line antiretroviral regimen

Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships

(2016) Andrew Mujugira et al.   AIDS RESEARCH AND HUMAN RETROVIRUSES

Total HIV-1 DNA, a Marker of Viral Reservoir Dynamics with Clinical Implications

(2016) Véronique Avettand-Fènoël et al.   CLINICAL MICROBIOLOGY REVIEWS

Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults

(2016) Huldrych F. Günthard et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study

(2016) Gisela Leierer et al.   Open Forum Infectious Diseases

Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials

(2015) François Raffi et al.   AIDS

Antiretroviral Regimen and Suboptimal Medication Adherence Are Associated With Low-Level Human Immunodeficiency Virus Viremia

(2015) C. Konstantopoulos et al.   Open Forum Infectious Diseases

Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor–Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1

(2014) Jeffrey L. Lennox et al.   ANNALS OF INTERNAL MEDICINE

Significant Reduction in HIV Virologic Failure During a 15-Year Period in a Setting With Free Healthcare Access

(2014) C. Delaugerre et al.   CLINICAL INFECTIOUS DISEASES

Clinical Implications of HIV-1 Minority Variants

(2013) Jonathan Z. Li et al.   CLINICAL INFECTIOUS DISEASES

Virologic Failure Following Persistent Low-level Viremia in a Cohort of HIV-Positive Patients: Results From 12 Years of Observation

(2013) C. Laprise et al.   CLINICAL INFECTIOUS DISEASES

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection

(2013) Jürgen K. Rockstroh et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load

(2012) JR Arribas et al.   HIV MEDICINE

Risk factors for raltegravir resistance development in clinical practice

(2012) I. Malet et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antiretroviral Drug Resistance in HIV-1–Infected Patients Experiencing Persistent Low-Level Viremia During First-Line Therapy

(2011) Babafemi Taiwo et al.   JOURNAL OF INFECTIOUS DISEASES

Long-term trends in adherence to antiretroviral therapy from start of HAART

(2010) Valentina Cambiano et al.   AIDS

Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses

(2010) Jeffrey L Lennox et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A large French prospective cohort of HIV-infected patients: the Nadis Cohort

(2009) P Pugliese et al.   HIV MEDICINE

Emergence of Drug Resistance in HIV Type 1–Infected Patients after Receipt of First‐Line Highly Active Antiretroviral Therapy: A Systematic Review of Clinical Trials

(2008) Ravindra Gupta et al.   CLINICAL INFECTIOUS DISEASES